Nonetheless, using a previously published empirical survival model (5), the study has substantial practical relevance (Table 1). As suggested by Afilalo et al. (3), an 85-year-old man with known disease has a greater baseline risk (18.8% vs. 1.3%), and therefore obtains a greater benefit (8.9% vs. 0.4%) from statin treatment compared with an otherwise similar 55-year-old man. Thus, although the absolute gain in survival is lower in the 85-year-old (2.1 vs. 4.3 years), it is proportionately greater (75% vs. 23%) relative to baseline expectations of survival (2.8 vs. 18.8 years). All things being equal, then, the older we become, the more value we should ascribe to each additional year of life (and to the treatment that provides it).